BCL2 (B-Cell Lymphoma 2)

BCL2 (B-Cell Lymphoma 2)

<div class="infobox" style="float: right; width: 300px; background: #f8f9fa; padding: 15px; border: 1px solid #ddd; margin-left: 20px;">

BCL2 Quick Reference

UniProt ID: [P10415](https://www.uniprot.org/uniprot/P10415)

Gene: [BCL2](/genes/bcl2)

Molecular Weight: 26 kDa

Subcellular Localization: Mitochondrial outer membrane, ER, nuclear envelope

Protein Family: BCL-2 family (anti-apoptotic subfamily)

Key Domains:

• BH4 domain (N-terminal)
• BH3 domain
• BH1 domain
• BH2 domain
• Transmembrane domain (C-terminal)

PDB Structures: [1G5M](https://www.rcsb.org/structure/1G5M), [2O2F](https://www.rcsb.org/structure/2O2F), [4AQ3](https://www.rcsb.org/structure/4AQ3)

</div>

Overview

BCL2 (B-Cell Lymphoma 2) is the founding member of the BCL-2 protein family and a central regulator of the intrinsic (mitochondrial) [apoptosis](/entities/apoptosis) pathway[@tsujimoto1984]. As an anti-apoptotic protein, BCL2 protects cells from programmed cell death by preventing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release[@kroemer2000]. In neurodegeneration, BCL2 dysfunction contributes to neuronal vulnerability, while therapeutic strategies aim to enhance BCL2 activity to protect [neurons](/entities/neurons) from apoptosis[@cory2002].

Structure and Domains

BCL-2 Homology (BH) Domains

BCL2 contains four BCL-2 homology domains that mediate protein-protein interactions[@youle2008]:

...

BCL2 (B-Cell Lymphoma 2)

<div class="infobox" style="float: right; width: 300px; background: #f8f9fa; padding: 15px; border: 1px solid #ddd; margin-left: 20px;">

BCL2 Quick Reference

UniProt ID: [P10415](https://www.uniprot.org/uniprot/P10415)

Gene: [BCL2](/genes/bcl2)

Molecular Weight: 26 kDa

Subcellular Localization: Mitochondrial outer membrane, ER, nuclear envelope

Protein Family: BCL-2 family (anti-apoptotic subfamily)

Key Domains:

• BH4 domain (N-terminal)
• BH3 domain
• BH1 domain
• BH2 domain
• Transmembrane domain (C-terminal)

PDB Structures: [1G5M](https://www.rcsb.org/structure/1G5M), [2O2F](https://www.rcsb.org/structure/2O2F), [4AQ3](https://www.rcsb.org/structure/4AQ3)

</div>

Overview

BCL2 (B-Cell Lymphoma 2) is the founding member of the BCL-2 protein family and a central regulator of the intrinsic (mitochondrial) [apoptosis](/entities/apoptosis) pathway[@tsujimoto1984]. As an anti-apoptotic protein, BCL2 protects cells from programmed cell death by preventing mitochondrial outer membrane permeabilization (MOMP) and cytochrome c release[@kroemer2000]. In neurodegeneration, BCL2 dysfunction contributes to neuronal vulnerability, while therapeutic strategies aim to enhance BCL2 activity to protect [neurons](/entities/neurons) from apoptosis[@cory2002].

Structure and Domains

BCL-2 Homology (BH) Domains

BCL2 contains four BCL-2 homology domains that mediate protein-protein interactions[@youle2008]:

| Domain | Residues | Function |
|--------|----------|----------|
| BH4 | 10-30 | Anti-apoptotic function; stabilizes structure |
| BH3 | 93-107 | Pro-apoptotic protein binding groove |
| BH1 | 136-155 | Hydrophobic groove formation |
| BH2 | 187-202 | Completes binding groove |
| TM | 219-239 | Membrane anchoring |

Three-Dimensional Structure

BCL2 adopts a globular fold with[@petros1996]:

• Seven α-helices surrounding a central hydrophobic groove
• The BH3-binding groove accommodates pro-apoptotic partners
• C-terminal transmembrane helix for membrane insertion

Membrane Localization

BCL2 localizes primarily to[@krajewski1997]:

• Mitochondrial outer membrane (primary site)
• Endoplasmic reticulum
• Nuclear envelope

The transmembrane domain anchors BCL2 to these membranes, positioning it to regulate apoptosis.

BCL-2 Family Overview

The BCL-2 family is divided into three functional groups[@czabotar2014]:

Anti-Apoptotic Members

• BCL2, BCL-XL (BCL2L1), MCL1, BCL-W (BCL2L2), BFL1/A1 (BCL2A1), BCL2L13
• Contain all four BH domains
• Protect against apoptosis

Pro-Apoptotic Effectors (BH3-only)

• BAX, BAK, BOK
• Contain BH1-3 domains
• Execute MOMP when activated

BH3-Only Initiators

• BID, BIM (BCL2L11), BAD, NOXA (PMAIP1), PUMA (BBC3), BMF, HRK, BIK
• Contain only BH3 domain
• Sense cellular stress and activate effectors

Normal Function

Apoptosis Regulation

BCL2 inhibits apoptosis through multiple mechanisms[@edlich2011]:

Direct BAX/BAK inhibition

• BCL2 binds BAX/BAK via BH3 groove
• Prevents BAX/BAK oligomerization
• Blocks MOMP

BH3-only protein sequestration

• Traps activators (BIM, tBID)
• Prevents effector activation
• Acts as "sink" for pro-death signals

Mitochondrial membrane stabilization

• Maintains outer membrane integrity
• Prevents cytochrome c release
• Blocks apoptosome formation

Calcium Homeostasis

At the ER, BCL2[@rong1999]:

• Regulates IP3 receptor activity
• Controls calcium release to mitochondria
• Prevents calcium overload-induced apoptosis

Autophagy Regulation

BCL2 binds Beclin-1 (ATG6) and[@pattingre2005]:

• Inhibits [autophagy](/entities/autophagy) initiation
• Releases Beclin-1 under stress
• Coordinates apoptosis and autophagy

Role in Neurodegeneration

Alzheimer's Disease

BCL2 dysregulation in AD includes[@macgibbon1997]:

Findings:

• Decreased BCL2 expression in vulnerable neurons
• Reduced BCL2/BAX ratio (pro-apoptotic shift)
• Altered BCL2 phosphorylation
• BCL2 oxidation impairs function

Consequences:

• Enhanced neuronal susceptibility to [Aβ](/proteins/amyloid-beta) toxicity
• Increased oxidative stress vulnerability
• Accelerated synaptic apoptosis

Parkinson's Disease

In PD, BCL2 plays a protective role[@offen1998]:

Evidence:

• BCL2 overexpression protects dopaminergic neurons
• MPTP toxicity associated with BCL2 downregulation
• BCL2 polymorphisms linked to PD susceptibility
• Reduced BCL2 in substantia nigra

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin) affects BCL2[@chen2008]:

• Decreases BCL2 transcription via p53
• Promotes BCL2 degradation
• BCL2 overexpression rescues HD models

Stroke and Ischemia

BCL2 is neuroprotective in cerebral ischemia[@martinou1994]:

• BCL2 transgenic mice show reduced infarct size
• BCL2 upregulation correlates with survival
• Delayed neuronal death involves BCL2 loss

ALS

Motor neurons show BCL2 abnormalities[@mu2006]:

• Reduced BCL2 in spinal cord
• Mutant SOD1 decreases BCL2 expression
• BCL2 overexpression extends survival in models

Therapeutic Targeting

BCL2 Enhancement Strategies

| Approach | Agent/Mechanism | Status |
|----------|-----------------|--------|
| Gene therapy | AAV-BCL2 delivery | Preclinical |
| Pharmacologic upregulation | [HDAC](/entities/hdac-enzymes) inhibitors, retinoids | Research stage |
| BH3 mimetics (cancer) | Venetoclax (BCL2 inhibitor) | FDA-approved (cancer); NOT for neurodegeneration |
| Peptide inhibitors | Stapled peptides | Research stage |

BH3 Mimetics: Cancer vs. Neurodegeneration

Important distinction: BH3 mimetics (like venetoclax) INHIBIT BCL2 and are used in cancer to promote tumor cell death. For neurodegeneration, the opposite approach is needed – enhancing BCL2 activity or expression[@ashkenazi2022].

| Context | Strategy | Goal |
|---------|----------|------|
| Cancer | BCL2 inhibition | Kill cancer cells |
| Neurodegeneration | BCL2 enhancement | Protect neurons |

Indirect Approaches

• Growth factors (BDNF, GDNF) upregulate BCL2
• Antioxidants preserve BCL2 function
• Anti-inflammatory agents prevent BCL2 loss
• Exercise increases BCL2 expression

Key Protein Interactions

| Partner | Function | Disease Relevance |
|---------|----------|-------------------|
| BAX | Pro-apoptotic effector | MOMP execution |
| BAK | Pro-apoptotic effector | MOMP execution |
| BIM | BH3-only activator | Stress sensing |
| tBID | Truncated BID | Death receptor pathway |
| BAD | BH3-only sensitizer | Growth factor signaling |
| Beclin-1 | Autophagy regulator | Autophagy inhibition |
| IP3R | Calcium channel | ER calcium regulation |

Regulation

Transcriptional Control

BCL2 transcription is regulated by[@kirsch1999]:

• [NF-κB](/entities/nf-kb) – Pro-survival transcription factor
• CREB – cAMP response element
• p53 – Downregulates BCL2
• STAT3 – Survival signaling

Post-Translational Modifications

| Modification | Site | Effect |
|--------------|------|--------|
| Phosphorylation | Ser70 | Activity regulation |
| Phosphorylation | Thr69 | Reduced function |
| Ubiquitination | Various | Proteasomal degradation |
| Oxidation | Cys residues | Loss of function |

Protein Stability

BCL2 stability is influenced by:

• Proteasome-mediated degradation
• Caspase cleavage during apoptosis
• Oxidative damage

Biomarker Potential

• BCL2/BAX ratio – Indicator of apoptotic susceptibility
• BCL2 expression – In blood cells as surrogate marker
• BCL2 phosphorylation – Activity status readout

Animal Models

BCL2 transgenic mice[@duboisdauphin1994]:

• Neuron-specific overexpression
• Protected from ischemia, excitotoxicity
• Resistance to axotomy-induced death

BCL2 knockout mice:

• Viable but with lymphoid abnormalities
• Increased neuronal vulnerability
• Enhanced sensitivity to toxins

See Also

• [Apoptosis](/mechanisms/apoptosis)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
• [BAX Protein](/proteins/bax-protein)
• Cytochrome C
• BCL2 Gene

Pathway Diagram

The following diagram shows key molecular relationships for BCL2 (B-Cell Lymphoma 2) based on knowledge graph edges:

Pathway Diagram

The following diagram shows the key molecular relationships involving BCL2 (B-Cell Lymphoma 2) discovered through SciDEX knowledge graph analysis: